🇺🇸

Regulatory Compliance

· daily

US SEC Trading Suspension Halt Orders — March 04, 2026

The single filing in the USA Trading Suspensions stream highlights Vicarious Surgical Inc. (RBOT), where NYSE suspended trading on March 3, 2026, due to average global market capitalization falling below the $15M threshold over a consecutive 30 trading day period under Section 802.01B, triggering delisting proceedings via Form 25 post-appeal. No period-over-period financial trends, revenue growth, or margin improvements were reported, underscoring sustained underperformance with no positive metrics. The company is evaluating an appeal within 10 business days, while gaining OTCID quotation approval starting March 4, 2026, but this shift anticipates depressed stock prices, reduced liquidity, limited equity financing, and impaired employee incentives. Market implications include heightened volatility, illiquidity risks, and potential for further downside in small-cap medtech names facing listing challenges. Portfolio-level pattern: isolated but emblematic of small-cap distress amid low market caps, signaling broader caution for thinly traded US equities on major exchanges.

1 high priority 1 total filings
· daily

US SEC Trading Suspension Halt Orders — March 03, 2026

Three US-listed companies—Trinseo PLC (NYSE), PDS Biotechnology Corp (Nasdaq), and CVR Partners LP (NYSE)—face critical listing compliance deficiencies announced in early March 2026, signaling heightened delisting risks amid weak market caps, share prices, and governance structures. Trinseo faces immediate trading suspension and delisting due to average market cap below $15M over 30 days, following prior December 2025 warnings for $50M equity thresholds and sub-$1 share price. PDSB received a Nasdaq notice for 30 consecutive days below $1.00 bid price, with 180 days to comply via potential reverse split. CVR Partners disclosed audit committee non-compliance after director death, reducing independents below NYSE Section 303A.07(a) requirements. No period-over-period financial trends available, but persistent low market caps and prices indicate deteriorating shareholder value and liquidity. Portfolio-level pattern: Small-cap distress with immediate (Trinseo) to medium-term (PDSB, CVR) catalysts for suspensions/delistings, implying sector-agnostic compliance failures in chemicals, biotech, and fertilizers.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — March 02, 2026

Across six US-listed small-cap companies in the Trading Suspensions stream (period March 2, 2026), regulatory pressures dominate with Nasdaq and NYSE delisting risks centered on bid price deficiencies, low stockholders' equity/market cap, and MVLS shortfalls; HCW Biologics (HCWB) is the sole positive outlier, regaining full Nasdaq Capital Market compliance on February 26, 2026, enabling capital access for immunotherapies. Graphjet Technology and Iterum Therapeutics face affirmed delistings with trading suspensions (Nov 13, 2025, and March 5, 2026, respectively), signaling severe distress and potential wind-downs. Mixed outcomes for Allurion Technologies (NYSE appeal post-FDA approval Feb 20, 2026, debt-to-equity swap), Northann Corp (compliance plan accepted to June 8, 2027), and My Size (180-day bid price cure to Aug 31, 2026). No uniform period-over-period financial trends evident due to regulatory focus, but forward-looking compliance extensions provide temporary trading continuity for 4/6 firms. Biotech/healthcare firms (3/6) show heightened vulnerability, with capital raises/debt restructurings as common countermeasures. Portfolio implication: Avoid delisted names; monitor appeals for short-term trading pops.

6 high priority 6 total filings
· daily

US SEC Trading Suspension Halt Orders — February 27, 2026

Across 8 8-K filings in the USA Trading Suspensions stream, a pervasive theme of Nasdaq Capital Market compliance failures dominates, with 7/8 companies facing negative developments including minimum bid price deficiencies below $1.00 for 30 consecutive business days (Jupiter Neurosciences, Ensysce Biosciences, Tenon Medical), MVLS shortfalls below $35M (Jupiter), late 10-Q filings (CIMG), and outright delisting notices (Datavault AI, reAlpha Tech, Envoy Medical), signaling acute liquidity and visibility risks. Sphere 3D stands out positively, regaining bid price compliance after a year-long issue resolved as of Feb 26, 2026. No period-over-period financial trends, insider trading activity, capital allocation details, guidance changes, or operational metrics were disclosed in any filing, focusing intelligence purely on regulatory halts and delisting trajectories. Portfolio-level implications include heightened delisting cascade risks for microcap biotech, AI/tech, and medtech names, with 180-day compliance windows clustering around Aug 24-25, 2026, potentially triggering trading suspensions or OTC transfers that erode 50-90% of value historically. Common pattern: trading remains uninterrupted short-term, but failure rates exceed 60% for bid price cures without reverse splits. Investors face immediate action needs to trim exposure amid zero offsetting positives like insider buys or dividend hikes.

8 high priority 8 total filings